» Articles » PMID: 30472831

Protective Effect of Naringin on DSS-Induced Ulcerative Colitis in Mice

Overview
Date 2018 Nov 27
PMID 30472831
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Peroxisome proliferator-activated receptor γ (PPARγ) is an important member of the nuclear receptor superfamily. Previous studies have shown the satisfactory anti-inflammatory role of PPARγ in experimental colitis models, mainly through negatively regulating several transcription factors such as nuclear factor-κB (NF-κB). Therefore, regulating PPARγ and PPARγ-related pathways has great promise for treating ulcerative colitis (UC). In the present study, our objective was to explore the potential effect of naringin on dextran sulfate sodium (DSS) induced UC in mice and its involved potential mechanism. We found that naringin significantly relieved DSS-induced disease activities index (DAI), colon length shortening, and colonic pathological damage. Exploration of the potential mechanisms demonstrated that naringin significantly activated DSS-induced PPARγ and subsequently suppressed NF-κB activation. PPARγ inhibitor GW9662 largely abrogated the roles of naringin in vitro. Moreover, DSS induced the activation of mitogen-activated protein kinase (MAPK) and (NOD)-like receptor family pyrin domain containing 3 (NLRP3) inflammasome was inhibited by naringin. Tight junction (TJ) architecture in naringin groups was also maintained by regulating zonula occludens-1 (ZO-1) expression. These results suggested that naringin may be a potential natural agent for protecting mice from DSS-induced UC.

Citing Articles

Identification and preliminary validation of biomarkers associated with mitochondrial and programmed cell death in pre-eclampsia.

Lin R, Weng X, Lin L, Hu X, Liu Z, Zheng J Front Immunol. 2025; 15:1453633.

PMID: 39916955 PMC: 11798957. DOI: 10.3389/fimmu.2024.1453633.


Network pharmacology integrated with molecular docking and molecular dynamics simulations to explore the mechanism of Shaoyao Gancao Tang in the treatment of asthma and irritable bowel syndrome.

Ren M, Ma J, Qu M Medicine (Baltimore). 2024; 103(50):e40929.

PMID: 39686413 PMC: 11651441. DOI: 10.1097/MD.0000000000040929.


Inflammasomes in Intestinal Disease: Mechanisms of Activation and Therapeutic Strategies.

Scalavino V, Piccinno E, Giannelli G, Serino G Int J Mol Sci. 2024; 25(23).

PMID: 39684769 PMC: 11642578. DOI: 10.3390/ijms252313058.


Harnessing the Anti-Inflammatory Properties of Polyphenols in the Treatment of Inflammatory Bowel Disease.

Boaru D, Fraile-Martinez O, De Leon-Oliva D, Garcia-Montero C, De Castro-Martinez P, Miranda-Gonzalez A Int J Biol Sci. 2024; 20(14):5608-5672.

PMID: 39494333 PMC: 11528451. DOI: 10.7150/ijbs.98107.


Preclinical studies of natural flavonoids in inflammatory bowel disease based on macrophages: a systematic review with meta-analysis and network pharmacology.

Shi S, Jiang H, Ma W, Guan Z, Han M, Man S Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39422746 DOI: 10.1007/s00210-024-03501-0.